Scott W. Morrison - 21 May 2026 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: Director
Issuer ticker: VERA
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2026, 16:24:18 UTC
Prior SEC filing: 16 Sep 2025
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Scott W. Morrison filed Form 4 for Vera Therapeutics, Inc. (VERA) on 26 May 2026.

Key facts

This page summarizes Scott W. Morrison's Form 4 filing for Vera Therapeutics, Inc. (VERA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2026, 16:24.

Change

Previous filing in this sequence was filed on 16 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001662426 Primary reporting owner

Morrison Scott W

Relationship: Director
Address: C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 26 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +17,084
Change %
Price: $0.000000^*
Shares after: 17,084
Date: 21 May 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 17,084
Exercise price: $34.35
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.